Dual-targeting mechanism designed for robust Blood-Brain Barrier (BBB) crossing. Enables highly efficient systemic delivery beyond brain vasculature directly into deep parenchymal cells.
High-efficiency plug-and-play loading of oligonucleotides (ASO, siRNA) directly to the NNP surface.
Stable intracellular transport and functional release of complex macromolecules including therapeutic enzymes.
Engineered to ensure robust endosomal escape, enabling complete cytoplasmic delivery of therapeutic payloads.
I-NNP targets CD47-high diseased tissues in inflammation, fibrosis, and autoimmunity, combining CD47-SIRPα blockade with therapeutic payload delivery in one nanoparticle.
I-NNP uses surface SIRPα to bind CD47-high diseased cells, enabling active homing to inflammatory, fibrotic, and autoimmune tissue sites.
By blocking the CD47-SIRPα "don't eat me" signal, I-NNP adds immune-modulating activity directly into the delivery carrier.
The same CD47-guided carrier can be adapted with ASO, siRNA, or protein payloads to build disease-specific therapeutic pipelines.
Delivery platforms · I-NNP · B-NNP
One NNP technology. Two delivery platforms, each designed around a biological route to its target.
I-NNP / IMMUNE-MEDIATED DISEASES
I-NNP homes to CD47-high inflamed and fibrotic tissue, with CD47 blockade built in.
Surface SIRPα engages CD47 and supports CD47 blockade.
The same NNP can carry ASO, siRNA and macromolecule cargos to inflamed and fibrotic tissue.
Disease areas · mouse models
Reaches inflamed colon.
Reaches fibrotic lung.
Reaches injured liver.
Reaches inflamed kidney.
B-NNP / CNS DISORDERS
Blood–brain barrier (BBB) crossing for CNS delivery: one surface motif docks at the barrier, and the other supports receptor-mediated transcytosis.
Supports docking at the blood–brain barrier.
Supports receptor-mediated transcytosis across the barrier.
BBB-crossing delivery
Systemic delivery past brain vessels.
Reaches brain parenchyma beyond the vessels.
RNA and macromolecule payloads into deep parenchymal cells.
